{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-25-000013","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.715020+00:00","generated_at":"2026-05-22T05:08:31.338447+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Therapeutics Q1 net loss $18.1M; cash $92M; WTX-124 data/FDA in H2 2025","bullets":["Net loss of $18.1M in Q1 2025 vs $16.2M in Q1 2024; R&D spend $13.1M.","Cash and equivalents $92.0M as of March 31, 2025; runway into Q4 2026.","WTX-124 Phase 1/1b on track for interim data and FDA regulatory discussions in H2 2025.","First patient dosed in WTX-330 Phase 1b/2 trial; initial Phase 1 data showed clinical activity and tolerability.","INDUCER T cell engager development candidate expected by end of Q2 2025; PREDATOR masking shown to silence peripheral activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-25-000013","json":"https://secwatch.observer/filing/0001785530-25-000013.json","markdown":"https://secwatch.observer/filing/0001785530-25-000013.md","text":"https://secwatch.observer/filing/0001785530-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000013/0001785530-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000013/howl-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:08:31.338447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}